Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: a Large, Single Institution Experience.

Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: a Large, Single Institution Experience.

J Minim Invasive Gynecol. 2017 Oct 25;:

Authors: Valerio G, Conte C, Teresa GM, Camilla N, Giuseppe V, Salvatore GA, Stefano C, Claudio L, Andrea DG, Maria RA, Anna F, Giovanni S, Gabriella F

Abstract
STUDY OBJECTIVE: To analyze the feasibility and safety of laparoscopic secondary cytoreductive surgery in a retrospective series of platinum sensitive recurrent ovarian cancer patients.
DESIGN: Retrospective cohort study (Canadian Task Force classification II-2).
SETTING: Catholic University of the Sacred Hearth, Rome, Italy.
PATIENTS: Between October 2010 and October 2016, 58 patients with recurrent ovarian cancer were selected for a retrospective analysis of data.
INTERVENTIONS: All patients underwent a laparoscopic secondary cytoreduction with single or multiple procedures.
RESULTS: The most frequent pattern of recurrence was represented by the peritoneal one (48.3%); there were 6 patients (10.3%) experiencing parenchymal disease (spleen=5, liver=1), and 24 patients (41.4%) presenting lymph node recurrence. Complete debulking was achieved for 100% of the patients. The median operative time was 204 minutes (range 55-448), estimated blood loss was70 mL (range 20-300), and the median length of hospital stay was 4 days (range 1-21). There were 4 (6.8%) intra-operative complications. Early post-operative complications were documented in 6 patients (10.3%), but only one G3 complication. The median follow-up since secondary cytoreduction was 24 months (range: 9-71). There were 21 cases (36.2%) experiencing second relapse of disease; the median progression free survival (PFS) was 28 months (2-yr PFS: 58.7%). We documented 5 cases experiencing death of disease (8.6%) patients; the 2-yr OS rate was 90.7%.
CONCLUSIONS: For selected patients, laparoscopy is a feasible and safe approach to optimal cytoreduction for patients with recurrent ovarian cancer.

PMID: 29081384 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2z7VY1A